Metrics as of 10/16/2026, 04:28 PM (Berlin time), refresh in progress.
Supernus Pharmaceuticals Stock
Supernus Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Jack A. Khattar
- Employees
- 778
- Market cap
- $2.3 B
- IPO
- 01/05/2012
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm in the Healthcare sector dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Headquartered in Rockville, the company was established in 2005 and currently employs 778 employees. Its portfolio of…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Supernus Pharmaceuticals stock: price history
1D
-1.7%
1W
-8.9%
1M
-6.0%
6M
-24.3%
YTD
-21.8%
1Y
-21.9%
2Y
+14.4%
5Y
+22.8%
10Y
+86.8%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~8% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Supernus Pharmaceuticals
Analyst assessment of Supernus Pharmaceuticals
PRICE TARGET LOW
US$40.00
CONSENSUS
US$57.60
MEDIAN
US$63.00
PRICE TARGET HIGH
US$65.00
0
STRONG BUY
9
BUY
5
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 09/07/2026
Supernus Pharmaceuticals stock metrics
P/E
-20.15
P/B
2.18
EV/EBITDA
-133.23
RETURN ON EQUITY
-5.7%
NET MARGIN
-26.6%
DEBT/EQUITY
0.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.7%
FLOAT SHARES
54,534,846
AVG. DAILY VOLUME (30D)
701,425
Insider transactions (SEC)
DEC TIMOTHY C
DEC TIMOTHY C
Bhatt Padmanabh P.
Bhatt Padmanabh P.
Khattar Jack A.
Institutional holders
Comparable stocks
Frequently asked questions about Supernus Pharmaceuticals stock
What does Supernus Pharmaceuticals do?
Supernus Pharmaceuticals, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Jack A. Khattar, the company employs around 778 people.
The IPO was on 01/05/2012; the stock trades on NASDAQ under the ticker SUPN.
What do analysts say about Supernus Pharmaceuticals stock?
14 analysts rate the stock, the consensus is Buy (as of 09/07/2026).
The average price target is US$57.60, ranging from US$40.00 to US$65.00, with a median of US$63.00.
This is an external assessment, not a statement by Market Jury.
When does Supernus Pharmaceuticals report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 8% stronger than usual.
Does Supernus Pharmaceuticals pay a dividend?
No, Supernus Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Supernus Pharmaceuticals?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Supernus Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Supernus Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.